DalsnaFinance

In Merck’s trial, median time to cancer worsening or death was 38.2 months on Keytruda, versus 8.4 on chemo.

Stocks Stock Titan By Stock Titan 26 Oct 2026 15:42 1 min read
In Merck’s trial, median time to cancer worsening or death was 38.2 months on Keytruda, versus 8.4 on chemo.

In Merck’s trial, median time to cancer worsening or death was 38.2 months on Keytruda, versus 8.4 on chemo.  Stock Titan

Read the full story on Stock Titan → Opens the original article on news.google.com

Summary aggregated from Stock Titan's public RSS feed. The full reporting belongs to Stock Titan — please read it on their site.